J
Ji Youn Han
Researcher at University of Texas Health Science Center at San Antonio
Publications - 42
Citations - 7998
Ji Youn Han is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Lung cancer & Osimertinib. The author has an hindex of 21, co-authored 36 publications receiving 5564 citations. Previous affiliations of Ji Youn Han include Guangdong General Hospital & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S. Herbst,Paul Baas,Dong Wan Kim,Enriqueta Felip,Jose Luis Perez-Gracia,Ji Youn Han,Julian R. Molina,Joo Hang Kim,Catherine Dubos Arvis,Myung-Ju Ahn,Margarita Majem,Mary J. Fidler,Gilberto de Castro,Marcelo Garrido,Gregory M. Lubiniecki,Yue Shentu,Ellie Im,Marisa Dolled-Filhart,Edward B. Garon +18 more
TL;DR: In this article, the authors evaluated the efficacy of pembrolizumab for patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
Journal ArticleDOI
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
D. Ross Camidge,Hye Ryun Kim,Myung-Ju Ahn,James Chih-Hsin Yang,Ji Youn Han,Jong Seok Lee,Maximilian Hochmair,Jacky Yu-Chung Li,Gee Chen Chang,Ki Hyeong Lee,Cesare Gridelli,Angelo Delmonte,Rosario Garcia Campelo,Dong Wan Kim,Alessandra Bearz,Frank Griesinger,Alessandro Morabito,Enriqueta Felip,Raffaele Califano,Sharmistha Ghosh,Alexander I. Spira,Scott N. Gettinger,M. Tiseo,Neeraj Gupta,Jeff Haney,David Kerstein,Sanjay Popat +26 more
TL;DR: Among patients with ALK‐positive NSCLC who had not previously received an ALK inhibitor, progression‐free survival was significantly longer among patients who received brigatinib than among those who received crizotinib.
Journal ArticleDOI
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik,E. Felip,Remi Veillon,Hiroshi Sakai,Alexis B. Cortot,Marina Chiara Garassino,J. Mazieres,Santiago Viteri,Hélène Senellart,Jan van Meerbeeck,Jo Raskin,Niels Reinmuth,Pierfranco Conte,Dariusz M. Kowalski,Byoung Chul Cho,Jyoti D. Patel,Leora Horn,Frank Griesinger,Ji Youn Han,Young Chul Kim,Gee Chen Chang,Chen Liang Tsai,James Chih-Hsin Yang,Yuh Min Chen,Egbert F. Smit,Anthonie J. van der Wekken,Terufumi Kato,Dilafruz Juraeva,Christopher Stroh,Rolf Bruns,J. Straub,Andreas Johne,Jürgen Scheele,J. Heymach,Xiuning Le +34 more
TL;DR: Among patients with advanced NSCLC with a confirmed MET exon 14 skipping mutation, the use of tepotinib was associated with a partial response in approximately half the patients, and adverse events led to permanent discontinuation of tEPotinib in 11% of the patients.
Journal ArticleDOI
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Yi-Long Wu,Myung-Ju Ahn,Marina Chiara Garassino,Ji Youn Han,Nobuyuki Katakami,Hye Ryun Kim,Rachel Hodge,Paramjit Kaur,Andrew P. Brown,Dana Ghiorghiu,Vassiliki A. Papadimitrakopoulou,Tony Mok +11 more
TL;DR: Osimertinib demonstrated superior CNS efficacy versus platinum-pemetrexed in T790M-positive advanced NSCLC, and was reported the first comparative evidence of osimert inib CNS efficacy compared with platinum- pemetrexe from a phase III study.
Journal ArticleDOI
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V. Sequist,Ji Youn Han,Myung-Ju Ahn,Byoung Chul Cho,Helena A. Yu,Sang We Kim,James Chih-Hsin Yang,Jong Seok Lee,Wu Chou Su,Dariusz M. Kowalski,Sergey Orlov,Mireille Cantarini,Remy B. Verheijen,Anders Mellemgaard,Lone Ottesen,Paul Frewer,Xiaoling Ou,Geoffrey R. Oxnard +17 more
TL;DR: The combination of osimertinib and savolitinib has acceptable risk-benefit profile and encouraging antitumour activity in patients with MET-amplified, EGFR mutation-positive, advanced NSCLC, who had disease progression on a previous EGFR TKI.